Australian Dentists Endorse Smartee's Mandibular Repositioning Technology at Global Symposium in Kunming
KUNMING, China, July 11, 2025 /PRNewswire/ -- Smartee Denti-Technology recently welcomed orthodontic experts and partners from Australia at its Global Symposium in Kunming, China. The event offered a deep dive into Smartee's Mandibular Repositioning Technology and showcased its clinical applications, particularly the innovative S8-SGTB appliance for Class II skeletal malocclusions. Australian clinicians praised the device for its simultaneous orthopedic and orthodontic correction, shorter treatment duration, and patient-friendly design.
Dr. Knox Kim, Principal Dentist at Dental Clinic @ World Tower Sydney, shared:
"In the past, for treating Class II malocclusions in growing patients, we had to use twin-block appliances before starting aligner therapy. It took at least three to six months to see the improvement. But with Smartee, from my own experience, it only took about one or two weeks before the patient could notice the lower jaw was pushing forward. And when I show the patients and the patients' parents the before and after photos, they were very happy to see such a quick response and improvement."
Dr. Jenny J. Song from Blossom Dental Care added:
"Compared to traditional functional and fixed appliances, Smartee GS is intelligently designed to guide both mandible repositioning and teeth movement simultaneously. This not only reduces total treatment time but also improves the predictability of outcomes."
Dr. Sabrina Liu, a general dentist in Sydney, reflected:
"This seminar was eye-opening. The number of successful mandibular repositioning cases using Smartee GS aligners changed my perception of what clear aligners can achieve. I hope more dentists in Australia will learn about this technique to benefit their patients."
At the core of Smartee's Mandibular Repositioning Technology is S8-SGTB, a clear, non-invasive appliance designed to treat skeletal Class II discrepancies, minimizing the need for jaw surgeries or extractions. Engineered for both growing and adult patients, it integrates orthopedic and orthodontic functions in a single aligner-based solution.
Key features include:
Simultaneous mandibular repositioning and dental alignment
Anotomical occlusal splints and locking components for stable joint advancement
Minimizing need for extractions or surgeries
Discreet, comfortable design compared to bulky functional devices
The S8-SGTB represents Smartee's commitment to delivering clinically effective, patient-centered treatment paths for complex cases.
Learn more about Smartee Mandibular Repositioning, please visit https://www.smarteealigners.com/products/smartee-gs-mandibular-repositioning-aligners/
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/australian-dentists-endorse-smartees-mandibular-repositioning-technology-at-global-symposium-in-kunming-302503204.html
SOURCE Smartee Denti-Technology
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
28 minutes ago
- Medscape
EMA Recommends Eco-Friendly Inhaler for COPD
The European Medicines Agency (EMA) has recommended a change in composition for Trixeo Aerosphere, also known as Riltrava Aerosphere. Both drugs are used for maintenance treatment in a subset of adults with moderate-to-severe chronic obstructive pulmonary disease (COPD). The recomposition involves replacing the existing gas propellant, HFA-134a, with a low global warming-potential (GWP) gas alternative called HFO-1234ze(E). The propellant is used for drug delivery and is not an active medicine. AstraZeneca claims that the new propellant will lead to a 99.9% reduction in GWP and an 85% reduction in greenhouse gas emissions compared with current propellants. The company adds that its carbon footprint is similar to that of dry powder inhalers. The reformulation was approved by British regulators in May and is currently under review in other countries such as China. COPD is an umbrella term for a group of lung conditions, including emphysema and chronic bronchitis. Symptoms include shortness of breath, frequent chest infections, and persistent wheezing. Estimates suggest that around 36.5 million people had COPD in Europe in 2020, and that this number will increase to 49.5 million by 2050. Trixeo Aerosphere and Riltrava Aerosphere have three active ingredients: budesonide, glycopyrronium, and formoterol fumarate dihydrate. Budesonide is a glucocorticosteroid that exerts rapid, dose-dependent, anti-inflammatory action on the airways when inhaled. Meanwhile, glycopyrronium is a long-acting muscarinic antagonist and formoterol fumarate dihydrate is a selective beta2-adrenergic agonist. Both result in bronchodilation. The reformulation comes as the EU phases out high GWP gases for environmental reasons. The EMA reported that studies confirm the safety and efficacy of the reformulated medicine are equivalent to those of the currently approved product. The associated studies will be made available in the variation assessment report following the European Commission's final decision, which is expected in the coming weeks. Annie Lennon is a medical journalist. Her writing appears on Medscape, WebMD, and Medical News Today, among other outlets.
Yahoo
21 hours ago
- Yahoo
Abra Dental Expands Access to Quality Care with New Paterson, NJ Office
PATERSON, N.J., July 24, 2025--(BUSINESS WIRE)--Abra Dental, a leading provider of family and pediatric dental care, proudly announces the grand opening of its seventh location at 370 Broadway in Paterson, New Jersey. The new office is now open and accepting new patients from Paterson and the surrounding communities. With a commitment to providing high-quality, accessible dental care, Abra Dental's Paterson office features state-of-the-art technology and a compassionate, multilingual team skilled in serving patients of all ages. Services include preventive care, pediatric dentistry, orthodontics, emergency dental services, and more, all in a welcoming and family-friendly environment. "We are thrilled to bring Abra Dental's mission of accessible, high-quality dental care to the families of Paterson," said Dr. Michael Skolnick, Founder and CEO of Abra Health Group. "Our goal is to ensure that every member of the community has access to the dental services they need to achieve and maintain healthy smiles." Paterson Mayor André Sayegh welcomed Abra Dental's arrival, stating, "The opening of Abra Dental at 370 Broadway is a win for Paterson residents. Increasing access to quality healthcare, especially for children and families, is vital for our city's well-being and future. We're grateful to Abra Dental for investing in our community." Abra Dental is supported by Abra Health Group, a doctor-led dental support organization (DSO) headquartered in New Jersey. Abra Health Group provides administrative and operational support, allowing clinicians to focus on delivering excellent patient care. With a growing network across New Jersey, Pennsylvania, and Connecticut Abra Health Group is committed to expanding access to essential healthcare services in underserved communities. The new Paterson office joins a family of six Abra Dental locations throughout New Jersey, including offices in Newark, Elizabeth, Jersey City, Kearny. Abra Dental accepts most major insurance plans, including Medicaid and CHIP, helping to reduce barriers to care for local families. Appointments can be scheduled by calling (973) 221-8758 or visiting For more information about the Abra Health Group and Abra Dental please visit their respective websites at and About Abra Health Group Founded in 2008 by Doctors Michael and Brooke Skolnick, a husband-and-wife dental team, Abra Health Group includes a rapidly expanding family of dental practices. With multiple recent acquisitions and new locations opening regularly, the group includes several multi-specialty dental clinics for patients of all ages in Connecticut, New Jersey, and Pennsylvania. Our singular mission is to provide access to high-quality, affordable care to underserved communities. By firmly placing our patients first, we aim to deliver an exceptional experience as we improve their well-being. Our vision is to become a leading dental support organization to underserved communities in the areas that we serve. With over 1,000 employees across 3 states and 23 locations, our large-footprint practices can accommodate hundreds of patients every day in an inviting, comfortable environment for both patients and staff alike. View source version on Contacts Emmy AnsinelliAbra Health GroupEmail: eansinelli@ Group website: Abra Dental: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
WIRED
a day ago
- WIRED
An Inventor Is Injecting Bleach Into Cancerous Tumors—and Wants to Bring the Treatment to the US
Xuewu Liu, a Chinese inventor who has no medical training or credentials of any kind, is charging cancer patients $20,000 for access to an AI-driven but entirely unproven treatment that includes injecting a highly concentrated dose of chlorine dioxide, a toxic bleach solution, directly into cancerous tumors. One patient tells WIRED her tumor has grown faster since the procedure and that she suspects it may have caused her cancer to spread—a claim Liu disputes—while experts allege his marketing of the treatment has likely put him on the wrong side of US regulations. Nonetheless, while Liu currently only offers the treatment informally in China and at a German clinic, he is now working with a Texas-based former pharmaceutical executive to bring his treatment to America. They believe that the appointment of Robert F. Kennedy Jr. as health secretary will help 'open doors' to get the untested treatment—in which at least one clinic in California appears to have interest—approved in the US. Kennedy's Make America Healthy Again (MAHA) movement is embracing alternative medicines and the idea of giving patients the freedom to try unproven treatments. While the health secretary did not respond to a request for comment about Liu's treatment, he did mention chlorine dioxide when questioned about President Donald Trump's Operation Warp Speed during his Senate confirmation hearing in February, and the Food and Drug Administration recently removed a warning about substance from its website. The agency says the removal was part of a routine process of archiving old pages on its site, but it has had the effect of emboldening the bleacher community. 'Without the FDA's heavy-handed warnings, it's likely my therapy would have been accepted for trials years earlier, with institutional partnerships and investor support,' Liu tells WIRED. He says he wrote to Kennedy earlier this year urging him to conduct more research on chlorine dioxide. 'This quiet removal won't immediately change everything, but it opens a door. If mainstream media reports on this shift, I believe it will unlock a new wave of serious [chlorine dioxide] research.' For decades, pseudoscience grifters have peddled chlorine dioxide solutions—sold under a variety of names, such as Miracle Mineral Solution—and despite warnings and prosecutions, have continued to claim the toxic substance is a 'cure' for everything from HIV to Covid-19 to autism. There is no credible evidence to back up any of these claims, which critics have long labeled as nothing more than a grift. The treatments typically involve drinking liquid chlorine dioxide on a regular basis, using solutions with concentrations of chlorine dioxide of around 3,000 parts per million (ppm), which is diluted further in water. Liu's treatment, however, involves a much higher concentration of chlorine dioxide—injections of several milliliters of 20,000ppm—and, rather than drinking it, patients have it injected directly into their tumors. Liu claims he has injected himself with the solution over 50 times and suffered no side effects. 'This personal data point encouraged me to continue research,' he says.
